Corrigendum to 'quality of Life in Patients with BRAF-mutant Melanoma Receiving the Combination Encorafenib Plus Binimetinib: Results from a Multicentre, Open-Label, Randomised, Phase III Study (COLUMBUS)' [european Journal of Cancer 152 (2021) 116-128].

The authors regret that the second affiliation for Author Paola Queirolo was not included in the published paper. The full author details are given below and have been updated in the online article. Paola Queirolo p, v p Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy v Ospedale Policlinico San Martino IRCCS, Genoa, Italy The authors would like to apologise for any inconvenience caused. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)European Journal of CancerVol. 152PreviewIn COLUMBUS, treatment with encorafenib plus binimetinib in patients with advanced BRAF-mutant melanoma showed improved progression-free and overall survival with favourable tolerability compared to vemurafenib treatment. Here, results on health-related quality of life (HRQoL) are presented. Full-Text PDF